Market Cap$52.23B
P/E31.13x
PEG Ratio1.11
Div yield1.59%
Beta0.24
BDX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)13.22%
Price vs S&P 500 (4W)7.44%
PEG Ratio1.11
VGM Score58.60
P/E Ratio (Annual)31.13x
Indicated Dividend Yield (Annual)1.59%
BDX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $3.14 | $3.23 | +2.93%(+$0.09) | |
| Q1 2026 | $2.77 | $2.90 | +4.51%(+$0.13) | |
| Q4 2025 | $2.81 | $2.91 | +3.47%(+$0.10) | |
| Q3 2025 | $3.91 | $3.96 | +1.15%(+$0.05) | |
| Q2 2025 | $3.40 | $3.68 | +8.16%(+$0.28) |
BDX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.67
3.67
3.71
3.81
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
| PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
About Becton, Dickinson and Co.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, including needles, syringes, and sharps-disposal units, alongside prefilled devices, diagnostic instruments, reagents, and flow cytometry and cell-imaging systems. Following its 2025 spinoff, the company operates across four segments: Medical Essentials (34% of revenue), Interventional (28%), Connected Care (25%), and Biopharma (13%). International markets represent 43% of total sales.